Department of Nephrology, Chang Gung Memorial Hospital, Linkou, Taiwan, Republic of China.
PLoS One. 2012;7(11):e48481. doi: 10.1371/journal.pone.0048481. Epub 2012 Nov 20.
Renal transplant patients often have severe bone and mineral deficiencies. While the clinical effects of immunosuppressive agents like calcineurin inhibitors (CIs) and sirolimus on bone turnover are unclear, bisphosphonates are effective in bone recovery in these patients. Gender is significantly associated with osteoporosis and affects bone turnover, which is different in women and men. The effective gender-related site of action of bisphosphonates is unknown.
Initially, we enrolled 84 kidney recipients who had received their transplants at least 5 months ago; of these, 8 were excluded and 76 were finally included in the study. First bone mineral density (BMD) at the lumbar spine, hip, and femoral neck was determined using dual-energy X-ray absorptiometry (DXA) between September 2008 and March 2009. These 76 patients underwent a repeat procedure after a mean period 14 months. Immunosuppressive agents, bisphosphonates, patients' characteristics, and biochemical factors were analyzed on the basis of the BMD determined using DXA.
After the 14-month period, the BMD of lumbar spine increased significantly (from 0.9 g/cm(2) to 0.92 g/cm(2), p<0.001), whereas that of the hip and femoral neck did not. Ordinal logistic regression analysis was used to show that Fosamax improved bone condition, as defined by WHO (p = 0.007). The use of immunosuppressive agents did not affect bone turnover (p>0.05). Moreover, in subgroup analysis, Fosamax increased the BMD at the lumbar spine and the hipbone in males (p = 0.028 and 0.03, respectively) but only at the lumbar spine in females (p = 0.022).
After a long periods after renal transplantation, the detrimental effects of steroid and immunosuppressive agents on bone condition diminished. Short-term Fosamax administration effectively improves BMD in these patients. The efficacy of Fosamax differed between male and female renal transplant patients.
肾移植患者常伴有严重的骨和矿物质缺乏。虽然免疫抑制剂如钙调磷酸酶抑制剂(CIs)和西罗莫司对骨转换的临床影响尚不清楚,但双膦酸盐在这些患者的骨恢复中是有效的。性别与骨质疏松症显著相关,并影响骨转换,男性和女性的骨转换不同。双膦酸盐的有效性别相关作用部位尚不清楚。
最初,我们招募了 84 名肾移植受者,他们在 5 个月前接受了移植;其中 8 人被排除在外,最终有 76 人纳入研究。2008 年 9 月至 2009 年 3 月期间,使用双能 X 线吸收法(DXA)首次测定腰椎、髋部和股骨颈的骨密度(BMD)。这些患者在平均 14 个月后进行了重复检查。根据 DXA 测定的 BMD 分析免疫抑制剂、双膦酸盐、患者特征和生化因素。
14 个月后,腰椎 BMD 显著增加(从 0.9g/cm(2)增加至 0.92g/cm(2),p<0.001),而髋部和股骨颈 BMD 没有增加。有序逻辑回归分析表明,福善美(Fosamax)改善了世界卫生组织(WHO)定义的骨状况(p=0.007)。免疫抑制剂的使用并未影响骨转换(p>0.05)。此外,在亚组分析中,福善美增加了男性腰椎和髋部的 BMD(p=0.028 和 0.03,分别),但仅增加了女性腰椎的 BMD(p=0.022)。
肾移植后很长一段时间,类固醇和免疫抑制剂对骨状况的不利影响减弱。短期福善美治疗可有效改善此类患者的 BMD。福善美在男性和女性肾移植患者中的疗效不同。